NeuroVive Pharmaceutical announced that a collaboration agreement has been signed with Karolinska Institutet regarding development of the company’s compound NV556 for the treatment of mitochondrial myopathy.
Under the collaboration agreement, the team led by Prof. Hakan Westerblad at Karolinska Institutet will study NeuroVive’s cyclophilin inhibitor compound NV556 and its effects in experimental models of mitochondrial myopathy.
The Karolinska Institutet research team previously published results1) where they show that another cyclophilin inhibitor, ciclosporin, shows mitochondrial protective effects mediated through inhibition of cyclophilin D, resulting in prevention of muscle fiber weakness in an experimental model of mitochondrial myopathy. They have also shown that patients with mitochondrial myopathy have increased levels of cyclophilin D, the target for NeuroVive’s compound NV556. NV556 is expected to have higher specificity and tolerability than ciclosporin, which may facilitate better optimization of dosage.
“We are now adding mitochondrial myopathy to our genetic mitochondrial disease portfolio, which is very exciting. We are also very glad to be able to explore this area together with Hakan Westerblad’s skilled team at Karolinska Institutet and are looking forward to our continued collaboration”, said Magnus Hansson, Chief Medical Officer at NeuroVive.
This collaboration expands NeuroVive’s presence in the genetic mitochondrial disease field, which is a NeuroVive key focus area and where NeuroVive also develops its NVP015 compounds in mitochondrial respiratory chain diseases. The NV556 compound that is studied under this collaboration is targeting cyclophilin D, and has therefore a different and complementary mode of action than the NVP015 compounds which target the respiratory chain supporting cell energy production.